News
3h
Dealbreaker on MSNBioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion DealIn litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...
The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.
(Reuters) -British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for ...
Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...
It is not clear whether Prasad will still serve as the agency’s chief medical and scientific officer, Stat reports. Meanwhile, Center for Drug Evaluation and Research staff grill top drug regulator ...
GSK plc's experimental antibiotic, gepotidacin, has been granted priority review by the U.S. Food and Drug Administration ...
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...
A new pill that combats antibiotic-resistant strains of gonorrhoea has inched closer to approval in the US, after the US Food and Drug Administration (FDA) accepted GSK’s gepotidacin for priority ...
GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.
Austin family advocates for getting fully vaccinated for meningococcal disease after daughter lost her legs and fingers as a University of Texas freshman and helped inspire Lifetime movie.
BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...
London’s FTSE 100 confidently opened the week, advancing 0.3%, or 28.30 points, to 9,124.03, supported by gains in Diageo, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results